We propose that BRD4 represses transcription of p53 target genes, such that when BETi block repression in the context of p53 stabilization by MDM2i the p53 pathway is potently activated leading to enhanced anti-leukemia activity, compared to either drug alone. Here, BRD4 is linked to leukemia.